

Open access • Posted Content • DOI:10.1101/479493

First estimation of the scale of canonical 5' splice site GT>GC mutations generating wild-type transcripts and their medical genetic implications — Source link

Jin-Huan Lin, Jin-Huan Lin, Xin-Ying Tang, Arnaud Boulling ...+16 more authors


Institutions: French Institute of Health and Medical Research, Second Military Medical University, Cardiff University

Published on: 27 Nov 2018 - bioRxiv (Cold Spring Harbor Laboratory)

Topics: Intron and RNA splicing

Related papers:

- · Characterisation and quantification of F8 transcripts of ten putative splice site mutations
- Functional analysis of 22 splice-site mutations in the PHEX, the causative gene in X-linked dominant hypophosphatemic rickets
- · Abnormal mRNA splicing resulting from consensus sequence splicing mutations of ATP7B
- U2AF1 Mutations Cause Allele-Specific Alterations in 3' Splice Site Recognition in Myeloid Malignancies
- Analysis of F8 mRNA in haemophilia A patients with silent mutations or presumptive splice site mutations.



1 First estimation of the scale of canonical 5' splice site GT>GC

2 mutations generating wild-type transcripts and their medical genetic

3 implications

4

5	Jin-Huan Lin ^{1,2,3†} , Xin-Ying Tang ^{2,3†} , Arnaud Boulling ¹ , Wen-Bin Zou ^{2,3} , Emmanuelle Masson ¹ , Yann
6	Fichou ^{1,4} , Loann Raud ¹ , Marlène Le Tertre ¹ , Shun-Jiang Deng ^{2,3} , Isabelle Berlivet ¹ , Chandran Ka ^{1,4} ,
7	Matthew Mort ⁵ , Matthew Hayden ⁵ , Gerald Le Gac ^{1,4} , David N. Cooper ⁵ , Zhao-Shen Li ^{2,3} , Claude Férec ¹ ,
8	Zhuan Liao ^{2,3*} and Jian-Min Chen ^{1*}
9	
10	¹ EFS, Univ Brest, Inserm, UMR 1078, GGB, F-29200 Brest, France
11	² Department of Gastroenterology, Changhai Hospital, the Second Military Medical University,
12	Shanghai, China
13	³ Shanghai Institute of Pancreatic Diseases, Shanghai, China
14	⁴ CHU Brest, Service de Génétique, Brest, France
15	⁵ Laboratory of Excellence GR-Ex, Paris, France
16	⁶ Institute of Medical Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom
17	
18	* To whom correspondence should be addressed. Tel: 33(2) 98 01 81 74; Fax: 33(2) 98 01 64 74;
19	Email: jian-min.chen@univ-brest.fr.
20	Correspondence may also be addressed to Zhuan Liao. Email: <u>liaozhuan@smmu.edu.cn.</u>
21	
22	[†] The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint

23 First Authors.

24 ABSTRACT

- 25 It has long been known that canonical 5' splice site (5'SS) GT>GC mutations may be compatible with
- 26 normal splicing. However, to date, the true scale of canonical 5'SS GT>GC mutations generating wild-
- 27 type transcripts, both in the context of the frequency of such mutations and the level of wild-type
- transcripts generated from the mutation alleles, remain unknown. Herein, combining data derived from a
- 29 meta-analysis of 45 informative disease-causing 5'SS GT>GC mutations (from 42 genes) and a cell
- 30 culture-based full-length gene splicing assay of 103 5'SS GT>GC mutations (from 30 genes), we
- estimate that ~15-18% of the canonical GT 5'SSs are capable of generating between 1 and 84% normal
- 32 transcripts as a consequence of the substitution of GT by GC. We further demonstrate that the
- canonical 5'SSs whose substitutions of GT by GC generated normal transcripts show stronger
- 34 complementarity to the 5' end of U1 snRNA than those sites whose substitutions of GT by GC did not
- 35 lead to the generation of normal transcripts. We also observed a correlation between the generation of
- 36 wild-type transcripts and a milder than expected clinical phenotype but found that none of the available
- 37 splicing prediction tools were able to accurately predict the functional impact of 5'SS GT>GC mutations.
- 38 Our findings imply that 5'SS GT>GC mutations may not invariably cause human disease but should also
- 39 help to improve our understanding of the evolutionary processes that accompanied GT>GC subtype
- 40 switching of U2-type introns in mammals.
- 41

42 **Keywords:** Canonical 5' splice site, Full-length gene splicing assay, Genotype and phenotype

- 43 relationship, Human Gene Mutation Database, Human inherited disease, Meta-analysis, Non-canonical
- 44 splice donor site, U2-type intron
- 45

46 INTRODUCTION

- 47 The vast majority of eukaryotic introns are spliced by the U2 spliceosome (the only alternative U12
- 48 spliceosome is responsible for <0.5% of all introns [1-3]), which interacts with RNA sequences
- 49 specifying the 5' and 3' splice sites [4, 5]. In vertebrates, the 9-bp consensus sequence for the U2-type
- 50 5' splice site (5'SS) has traditionally been described as 5'-MAG/GURAGU-3' (where M denotes C or A,
- 51 R denotes A or G and / denotes the exon-intron boundary; the corresponding nucleotide positions are
- 52 denoted -3_-1/+1_+6) although in reality this consensus sequence does not reflect the true extent of
- 53 sequence variability [6-11]. Base-pairing of this 9-bp sequence with 3'-GUCCAUUCA-5' at the 5' end of
- 54 U1 snRNA (Figure 1A) is critical for splicing to occur [10, 12-15]. Although the GT dinucleotide in the
- 55 first two intronic positions (in the context of DNA sequence) is the most highly conserved portion of the
- 56 U2-type 5'SS, it was reported, as early as 1983, that GC occasionally occurs in place of GT [16-18].
- 57 Subsequent genome-wide analyses have established that this non-canonical 5'SS GC is present as
- wild-type in ~1% of human U2-type introns [2, 7, 8, 19, 20]. Importantly, the remaining nucleotides in
- 59 these evolutionarily fixed non-canonical GC 5'SSs exhibit a stronger complementarity to the 3'-
- 60 GUCCAUUCA-5' sequence at the 5' end of U1 snRNA than those in the canonical GT 5'SSs (Figure
- 1A), thereby in all likelihood compensating for the decreased complementarity between the 5'SS and
- 62 the 5' end of U1 snRNA due to the U to C substitution [7, 8]. Comparative genome analyses have also
- revealed frequent switching of U2-type introns from the canonical 5'SS GT subtype to the non-canonical

bioRxiv preprint doi: https://doi.org/10.1101/479493; this version posted November 27, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

5'SS GC subtype during mammalian evolution [8, 21]. Finally, GC has recently been ranked first among
the six non-canonical 5'SSs identified by genome-wide RNA-seq analysis and splicing reporter assays
[22].

67 The finding that GC occasionally occurs instead of GT within the canonical 5'SS in some vertebrate 68 genes implies that substitution of the canonical 5'SS GT by GC (termed a 5'SS GT>GC mutation) may 69 allow normal splicing to occur. The first direct experimental evidence supporting such a postulate came 70 in the late 1980s; analyses of both the splicing products of *in vitro* transcribed rabbit beta globin (*Hbb*) RNA in a HeLa cell nuclear extract and the splicing products of the Hbb gene transiently expressed in 71 72 HeLa cells demonstrated that, of all the possible single nucleotide substitutions of the canonical 5'SS 73 GT of the second and last intron of *Hbb*, only the substitution of T by C was compatible with normal 74 splicing, albeit at a much reduced rate (approximately 10% of normal; see also Figure 1B) [23, 24]. 75 Further supporting evidence came from the study of disease-causing 5'SS GT>GC mutations, some of 76 which were reported to generate wild-type transcripts (see below). Additionally, the activation of cryptic 77 non-canonical 5'SS GC has also been reported as a consequence of some disease-causing mutations 78 [25, 26]. 79 The above notwithstanding, to date, the scale of canonical 5'SS GT>GC mutations generating wild-

80 type transcripts, both in the context of the frequency of such mutations and the level of wild-type

81 transcripts generated by such mutations, remain unknown owing to the intrinsic complexity of splicing

82 [11, 27-29] and the lack of suitable model systems for study. This issue has important implications for

83 medical genetics since mutant genotypes retaining even a small fraction of their normal function may

84 differ significantly from null genotypes in terms of their associated clinical phenotypes (e.g., only 5% of

85 normal *CFTR* gene expression is enough to prevent the lung manifestations of cystic fibrosis [30, 31]).

86 Herein, we attempted to address this issue by employing two distinct but complementary approaches in

87 concert.

88

89 RESULTS AND DISCUSSION

90 Estimation by Meta-Analysis of Disease-Causing 5'SS GT>GC Mutations

91 First, we performed a meta-analysis of disease-causing 5'SS GT>GC mutations logged in the

92 Professional version of Human Gene Mutation Database (HGMD; as of June 2017) [32], with a view to

93 generating an "*in vivo*" dataset to estimate the scale of 5'SS GT>GC mutations generating wild-type

94 transcripts. Employing a stringent approach (Figure 1C), we identified 45 disease-causing 5'SS GT>GC

95 mutations (from 42 genes) that were informative with respect to the presence or absence of wild-type

96 transcripts derived from the mutant allele (Table 1; see Supplementary Table S1 for more information

97 including affected intron, reference mRNA accession number, chromosomal location, hg38 coordinate,

98 and patient-derived tissue or cells used for RT-PCR analysis, etc.). It should be noted that the

assignments of "presence" or "absence" of mutant allele-derived wild-type transcripts depended upon

100 the agarose gel evaluation of RT-PCR products as described in the corresponding original publications.

101 Thus, we conservatively annotated an isolated case (i.e., the *PCCB* c.183+2T>C mutation), which was

102 not found to generate wild-type transcripts on agarose gel evaluation of RT-PCR products but was

found to generate <0.1% normal wild-type transcripts by means of quantitative RT-PCR [33], as
 generating no wild-type transcripts.

- 105 The 45 informative 5'SS GT>GC mutations comprised 30 homozygotes, 13 hemizygotes and 2 106 compound heterozygotes (Table 1). Whilst the presence or absence of wild-type transcripts derived 107 from the mutant allele was straightforward for all homozygous or hemizygous mutations included, the 108 two compound heterozygotes required special treatment. In the case of the CD3E c.520+2T>C 109 mutation, the pathogenic CD3E mutation in trans was a nonsense mutation in exon 6. Sequencing of the patient-derived, normal-sized RT-PCR products failed to demonstrate the exon 6 mutation, 110 suggesting that the wild-type transcripts were derived from the c.520+2T>C allele [34]. In the case of 111 112 the PNPLA2 c.757+2T>C mutation, the second PNPLA2 mutation in trans was a missense mutation, 113 c.749A>C (p.GIn250Pro). RT-PCR analysis detected only the c.749A>C mutant mRNA in skeletal 114 muscle of the patient, indicating the absence of detectable wild-type transcript emanating from the 115 c.757+2T>C allele [35].
- 116 15.6% (n=7) of the 45 informative mutations were found to have been capable of generating some 117 correctly spliced transcripts (Table 1). Information on the expression level of the mutant allele-derived 118 wild-type transcripts relative to that of the wild-type transcripts from a normal control (by definition, 119 100%) was available from four of the seven original publications (i.e., CD3E c.520+2T>C [34], CD40LG 120 c.346+2T>C [36], DMD c.8027+2T>C [37] and SLC26A2 c.-26+2T>C [38]), which ranged from 1-15% of 121 normal in individual cases (Table 1). All three of the remaining mutations generated both wild-type and 122 aberrant transcripts (i.e., CAV3 c.114+2T>C [39], PLP1 c.696+2T>C [40] and SPINK1 c.194+2T>C 123 [41]); based upon visual inspection of the original gel photographs, the relative expression level of the 124 mutant allele-derived wild-type transcripts in these three cases could also be estimated to fall within the 125 1-15% range.
- 126Taken together, the meta-analysis of disease-causing mutations suggests that 15.6% of 5'SS127GT>GC mutations retained the ability to generate between 1 and 15% correctly spliced transcripts
- relative to their wild-type counterparts.
- 129

130 Estimation from the Cell Culture-Based Full-Length Gene Splicing Assay of 5'SS GT>GC

131 Mutations

To corroborate the findings derived from the above "in vivo" dataset, we sought to generate an "in vitro" 132 dataset of 5'SS GT>GC mutations. In this regard, we have previously used a cell culture-based full-133 134 length gene splicing assay to analyze a series of SPINK1 intronic variants including a 5'SS GT>GC 135 mutation, c.194+2T>C [42, 43]. Specifically, the full-length 7-kb SPINK1 genomic sequence (including 136 all four exons plus all three introns of the gene) was cloned into the pcDNA3.1/V5-His-TOPO vector 137 [44]. The full-length gene splicing assay preserves better the natural genomic context of the studied 138 mutations as compared to the commonly used minigene splicing assay, a point of importance given the 139 highly context-dependent and combinatorial nature of alternative splicing regulation [45]. Moreover, the 140 full-length gene splicing assay can be readily used to evaluate all intronic variants including those 141 located near the first or last exons of the gene. Despite these advantages, the full-length gene assay 142 cannot easily be applied to large-size genes owing to the technical difficulties inherent in amplifying and

cloning long DNA fragments into the expression vector. Finally, it is pertinent to point out that, to

- system, it is highly desirable to use of cells of pathophysiological relevance owing to the tissue
- specificity of the splicing process in some instances [11, 27-29]. However, this may not always be
- 147 possible in practice, particularly if variants in multiple genes are to be analyzed in large-scale studies.

functionally evaluate the impact on splicing of any given gene mutation in a transient expression

- 148 For example, a recent study that measured 5'SS activity in the context of three minigenes was
- 149 performed in transfected HeLa cells [11]. In the present study, we used HEK293T cells for transfection
- as previously described [42, 46].

144

151 Bearing in mind the aforementioned advantages and disadvantages, we employed a cell culture-152 based full-length gene splicing assay (Figure 1C). In brief, for various technical and practical reasons, 153 we firstly selected genes whose genomic sizes did not exceed 8 kb (from the translation initiation codon 154 to the translation termination codon) and whose exons numbered ≥ 3 in order to construct full-length 155 gene expression vectors; we then screened genes, which had yielded a single or quasi-single band of expected size by means of RT-PCR analysis of transfected cells, for subsequent mutagenesis of all 156 157 available 5'SS GT dinucleotides in the construct (for details on the selected and screened genes, see 158 Supplementary Table S2). In the end, we succeeded in functionally analyzing 103 GT>GC mutations 159 from 30 different genes (Supplementary Table S3). 18.4% (n=19) of these artificially introduced 5'SS 160 GT>GC mutations generated wild-type transcripts (all confirmed by Sanger sequencing; Figure 2 and 161 Supplementary Figure S1), a finding that concurs with the 15.6% value obtained from the meta-analysis 162 of disease-causing 5'SS GT>GC mutations.

163 Only wild-type transcripts were observed for 10 of the aforementioned 19 5'SS GT>GC mutations 164 (e.g., FATE1 IVS1+2T>C in Figure 2B). In other words, no aberrantly spliced transcripts were observed 165 in these 10 cases. It is possible that aberrantly spliced transcripts may be rendered invisible by RNA degradation mechanisms such as nonsense-mediated mRNA decay (NMD) [47, 48]. One way to test 166 167 such a possibility is to add an NMD inhibitor such as cycloheximide [49] to the cell culture medium, although this is beyond the scope of the present study. We quantified the relative level of correctly 168 169 spliced transcripts for these 10 5'SS GT>GC mutations by means of our previously described quantitative RT-PCR method [46, 50, 51]. Here it is pertinent to mention that a co-transfected minigene 170 171 construct was used as an internal control in this analysis (Figure 3A), a prerequisite to obtain accurate 172 results. As shown in Figure 3B, the relative level of correctly spliced transcripts emanating from these 10 mutations is remarkably similar to that observed for the disease-causing 5'SS GT>GC mutations in 173 174 terms of the lowest extreme (2-5% vs. 1-5%); however, the functionally obtained highest level of 175 correctly spliced transcripts (84%) is much higher than the corresponding 15% value observed for the 176 disease-causing 5'SS GT>GC mutations (Table 1). We were initially puzzled by this disparity, but this 177 could be accounted for by two considerations. On the one hand, the currently analyzed disease-causing 178 mutations were likely to be biased toward those that generated either no wild-type transcripts or only a 179 low level. On the other hand, given (i) that 5'SS GC may occur as wild-type in the human genome, (ii) 180 the highly degenerate nature of the 5'SS splice signal sequences and (iii) the complex regulation of the 181 splicing process in vivo, it is entirely possible that a 5'SS GT>GC mutation may behave similarly to its

original wild-type sequence. This notwithstanding, no single GC mutation was noted to have an identical
or higher normal splicing activity than its 5'SS GT counterpart (Figure 3B).

Additionally, the single RT-PCR band of wild-type transcript size from either the wild-type *CCDC103* gene or the *CCDC103* IVS1+2T>C mutant (refer to Supplementary Figure S1) was revealed by Sanger sequencing to comprise the correctly spliced transcript and an alternatively spliced transcript; the level of the correctly spliced transcripts generated from the mutant allele was estimated to be ~18% of that generated from the wild-type allele based upon evaluation of the corresponding sequence peak heights (Supplementary Figure S2). By contrast, we did not attempt to quantify the relative expression level of correctly spliced transcripts for the remaining 8 GT>GC mutations due to the co-presence of aberrantly

- spliced transcripts (e.g., *DBI* IVS2+2T>C in Figure 2B). Nonetheless, based upon the relative intensities
- 192 of the wild-type and aberrant transcript bands (Figure 2; Supplementary Figure S1), we consider it
- unlikely that the relative expression level of correctly spliced transcripts in these cases will have fallen
- 194 outside of the above experimentally obtained 2-84% range.

Finally, we sequenced some aberrantly spliced transcripts (n=12), which resulted from exon skipping, retention of intronic sequence or deletion of partial exonic sequences (Table 2). Notably, the *PRSS2* IVS4+2T>C mutation activated a cryptic 5'SS GC that is located 15 bp upstream of the normal

- one, resulting in the deletion of the last 17 bp of exon 4 (i.e., the major band generated by *PRSS2*
- 199 IVS4+2T>C; Figure 2B).
- 200

201 Integrated Estimation from the Two Distinct but Complementary Datasets

- 202 We obtained remarkably similar findings in terms of both the frequency of 5'SS GT>GC mutations
- 203 generating wild-type transcripts and the lowest relative level of mutant allele-derived wild-type
- 204 transcripts from two quite distinct yet complementary datasets. The consistently lowest relative level of
- 205 mutant allele-derived wild-type transcripts across the two datasets suggested that the gel-based
- analytical method is sensitive enough to detect as little as ~1% of normally spliced transcripts. The
- 207 apparent disparity in terms of the highest relative level of mutant-derived wild-type transcripts between
- the two datasets can however be accounted for largely by the selection bias inherent to disease-causing
- 209 mutations. Therefore, we estimate that some 15-18% of 5'SS GT>GC mutations generate between 1
- and 84% of wild-type transcripts.
- 211

Exploration of the Mechanisms Underlying the Generation or Not of Wild-Type Transcripts by

213 5'SS GT>GC Mutations

- As mentioned above, canonical GT and non-canonical GC 5'SSs in the human genome exhibit different
- 215 patterns of sequence conservation, the latter showing stronger complementarity to the 3'-
- 216 GUCCAUUCA-5' sequence at the 5' end of U1 snRNA (Figure 1A). We surmised that the canonical
- 217 5'SSs whose substitutions of GT by GC generated normal transcripts (termed group 1) should also
- 218 exhibit stronger complementarity to the aforementioned 9-bp sequence than those sites whose
- substitutions of GT by GC did not lead to the generation of normal transcripts (termed group 2). We
- therefore extracted the 9-bp sequence tracts surrounding the corresponding groups of the 45 disease-
- 221 causing 5'SS GT>GC mutations (Supplementary Tables S1) and those of the 103 functionally analyzed

- 222 5'SS GT>GC mutations (Supplementary S3). Comparison of the resulting pictograms confirmed our
- postulate in both contexts, the respective pictograms for the combined group 1 mutations (n=26) and
- combined group 2 mutations (n=122) being provided in Figure 4. It should be emphasized that the surrounding 9-bp sequence tract is an important (but certainly not the only) factor in determining
- whether or not a given 5'SS GT>GC mutation will generate some wild-type transcripts. A simple
- example may be used to illustrate this point: the *DMD* c.8027+2T>C mutation (which generates 10% of
- wild-type transcripts) contrasts with the *NCAPD2* c.4120+2T>C mutation (which generates no wild-type
- transcripts) despite occurring in an identical 9-bp sequence tract, AAGGTATGA (see Supplementary
- 230 Table S1).
- We also explored whether the creation or disruption of splice enhancer/silencer motifs by the 5'SS GT>GC mutations could be associated with the generation or not of some wild-type transcripts. To this end, we employed ESEfinder and RESUE-ESE provided by the Alamut suite under default conditions. We were unable to draw any meaningful conclusions, primarily due to the short and degenerate nature of the splicing enhancer/silencer binding motifs.
- 236

Correlation Between the Retention of Wild-Type Transcripts and a Milder Than Expected Phenotype

- Given that even the retention of a small fraction of normal gene function may significantly impact the
 clinical phenotype, we reviewed the original publications describing the seven disease-causing 5'SS
 GT>GC mutations that generated at least some wild-type transcript (Table 1) with respect to the
- accompanying genotypic and phenotypic descriptions. In six cases, the mutations were specifically
- 243 described as being associated with mild clinical phenotypes as compared to their classical disease
- counterparts (see Supplementary Table S1). In the remaining case (SPINK1 c.194+2T>C), the original
- publication [41] was not informative in this regard; however, it is known that homozygosity for this
- 246 mutation causes chronic pancreatitis with variable expressivity [52] whereas null *SPINK1* genotypes
- 247 cause severe infantile isolated exocrine pancreatic insufficiency [53].
- 248 The above correlation between the retention of some wild-type transcripts and a milder than
- expected phenotype prompted us to postulate that 5'SS GT>GC mutations previously reported to confer
- a milder than expected phenotype but having no supportive patient-derived transcript expression data,
- 251 may be collectively associated with a non-canonical 5'SS GC signal. We collated a total of six such
- 252 mutations (i.e., *CYB5R3* c.463+2T>C [54], *HBB* c.315+2T>C [55], *HPRT* c.485+2T>C [56], *LAMB2*
- 253 c.3327+2T>C [57], *LMNA* c.1968+2T>C [58] and *MTTP* c.61+2T>C [59]; Supplementary Table S4). In
- this regard, two points require clarification. First, in two cases, patient-derived transcript expression data
- were available [56, 57]; these cases were however addressed here because the corresponding
- 256 expression data were insufficiently informative for them to be listed in Supplementary Table S1 (for
- 257 explanations, see Supplementary Table S4). Second, five of these six mutations (all germline) were
- 258 derived from the HGMD dataset whereas the remaining one (*LMNA* c.1968+2T>C) [58], a somatic
- 259 mutation, was obtained from a literature search; this somatic mutation was included owing to its clear
- 260 phenotypic impact. Pictogram analysis of the six corresponding 9-bp canonical 5'SSs did reveal a non-
- 261 canonical 5'SS GC signal (Supplementary Figure S3). Notably, one of the mutations affected the splice

- 8
- donor splice site of *HBB* intron 2 (i.e., *HBB* c.315+2T>C) [55], site of the previously analyzed
- orthologous mutation in the rabbit *Hbb* gene [23, 24]. We were able to study the effect of the *HBB* intron
- 264 2 GT>GC mutation on splicing by means of the full-length gene assay and found that it had indeed
- retained the ability to generate normal *HBB* transcripts (Figure 5).
- 266

267 Prediction of the Functional Effect of 5'SS GT>GC Mutations

- Finally, it is important to point out that none of the splicing prediction tools were able to accurately
- 269 predict the functional effect of 5'SS GT>GC mutations. For example, we analyzed the 45 disease-
- 270 causing 5'SS GT>GC mutations as well as the 19 functionally analyzed 5'SS GT>GC mutations that
- 271 generated some wild-type transcripts by means of the widely used Alamut[®] software suite under default
- 272 conditions. Whereas SpliceSiteFinder-like tended to predict a slightly reduced score, MaxEntScan,
- 273 NNSPLICE and GeneSplicer invariably gave no scores, for all mutations tested (Table 1;
- 274 Supplementary Table S3).
- 275

276 Conclusions

- 277 Based upon complementary data from the meta-analysis of 45 disease-causing 5'SS GT>GC mutations
- and the cell culture-based full-length gene splicing analysis of 103 5'SS GT>GC mutations, we have
- 279 provided a first estimate of ~15-18% for the proportion of canonical GT 5'SSs that are capable of
- 280 generating between 1 and 84% normal transcripts in case of the substitution of GT by GC. Extrapolation
- of the 15-18% value to the entire human genome implies that in at least 30,000 U2-type introns, the
- substitution of 5'SS GT by GC would result in the retention of partial ability to generate wild-type
- transcripts. Given that even the retention of 5% normal transcripts can significantly ameliorate a
- 284 patient's clinical phenotype, our findings imply the potential existence of hundreds or even thousands of
- disease-causing 5'SS GT>GC mutations that may underlie relatively mild clinical phenotypes. Given
- that 5'SS GT>GC mutations can also give rise to relatively high levels of wild-type transcripts, our
- findings imply that 5'SS GT>GC mutations may not invariably cause human disease. Apart from their
- direct implications for medical genetics, our findings may also help to improve our understanding of the
- evolutionary processes that accompanied the GT>GC subtype switching of U2-type introns in mammals[8, 21].
- 290 291

292 MATERIALS AND METHODS

293 Meta-Analysis of Disease-Causing 5'SS GT>GC Mutations

- Human disease-causing 5'SS GT>GC mutations logged in the Professional version of the Human Gene Mutation Database (HGMD; http://www.hgmd.cf.ac.uk/ac/index.php; as of June 2017) [32] were used as starting material. The procedure of the meta-analysis is described in Figure 1C.
- 297

298 Cell Culture-Based Full-Length Gene Splicing Assay

- 299 Outline of the cell culture-based full-length gene splicing assay is illustrated in Figure 1C.
- 300
- 301 *Amplification of full-length gene sequences*

302 For this experiment, we focused on genes whose genomic sizes were <8 kb (from the translation 303 initiation codon to the translation termination codon) and whose exons numbered \geq 3. Long-range PCR 304 was performed in a 25 µL reaction mixture containing 0.5 U KAPA HiFi HotStart DNA Polymerase (Kapa 305 Biosystems), 0.75 µL KAPA dNTP Mix (300 µM final), 5 µL 5 × KAPA HiFi Buffer, 50 ng DNA, and 0.3 306 μM forward and reverse primers (primer sequences available upon request). The PCR program 307 comprised an initial denaturation at 95°C for 5 min, followed by 30 cycles of denaturation at 98°C for 20 308 s, annealing at 66°C for 15 s, extension at 72°C for 1 min/kb, and a final extension at 72°C for 5 min. In 309 some of the cases where the desired fragments could not be obtained, a second amplification was 310 attempted: PCR was performed using 50 ng DNA in a 50 µL reaction mixture with 2.5 U TaKaRa LA 311 Taq DNA polymerase (TaKaRa), 8 μL dNTP Mixture (400 μM final), 5 μL 10 × LA PCR Buffer, and 1 μM 312 forward and reverse primers; thermal cycling conditions were initial denaturation at 94°C for 1 min, 30 313 cycles of denaturation at 98°C for 10 s, annealing and extension at 68°C for 1 min/kb, and a final 314 extension at 72°C for 10 min.

315

316 Cloning of the amplified full-length wild-type gene sequences into the expression vector

317 Early experiments were performed by means of TA cloning. In those cases in which the PCR products

318 contained multiple bands, the band of the expected size was gel purified using the QIAquick Gel

319 Extraction Kit (Qiagen) and 3'-A overhangs added; in cases where a single and expected band was

320 obtained, 3'-A overhangs were directly added to the PCR products amplified from the KAPA HiFi

HotStart DNA Polymerase (this step was omitted for those amplified using the TaKaRa LA Taq DNA

polymerase). The resulting products were cloned into the pcDNA3.1/V5-His-TOPO vector (Invitrogen) in

323 accordance with the manufacturer's instructions. Transformation was performed using Stellar

324 Competent Cells (TaKaRa) or XL10-Gold Ultracompetent Cells (Agilent Technologies). Transformed

cells were spread onto LB agar plates with 50 μg/mL ampicillin and incubated at 37°C overnight.

Plasmid constructs containing inserts in the right orientation were selected by PCR screening using the
 HotStarTag Master Mix Kit (Qiagen).

328 Later experiments were performed by mean

Later experiments were performed by means of in-fusion cloning. PCR products of the expected size were purified using the QIAquick Gel Extraction Kit (Qiagen) after gel electrophoresis. The purified

products were cloned into *EcoR*I restriction site of the linearized pcDNA3.1(+) vector with the In-Fusion

HD Cloning kit (TaKaRa) according to the manufacturer's instructions. Transformation was performed

using Stellar Competent Cells (TaKaRa) or XL10-Gold Ultracompetent Cells (Agilent Technologies).

333 Transformed cells were spread onto LB agar plates with 50 µg/mL ampicillin and incubated at 37°C

overnight. Plasmid constructs containing inserts were confirmed by PCR using the HotStarTaq Master

- 335 Mix Kit (Qiagen).
- 336

337 Mutagenesis

Variants were introduced into the wild-type full-length gene expression constructs by means of the

339 QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies). Mutagenesis was performed in

a 25.5 µL mixture containing 1.25 U PfuUltra HF DNA polymerase, 0.5 µL dNTP mix, 2.5 µL 10×

reaction buffer, 1.5 µL QuikSolution, 100 ng wild-type plasmid, and 62.5 ng each mutagenesis primer

- 342 (primer sequences available upon request). The PCR program had an initial denaturation at 95°C for 2
- min, followed by 18 cycles of denaturation at 95°C for 1 min, annealing at 60°C for 50 s, and extension
 at 68°C for 1 min/kb, and a final extension at 68°C for 7 min. The PCR products were transformed into
- 345 XL10-Gold Ultracompetent cells (Agilent Technologies) after treated with *Dpn*l at 37°C for 1 h.
- 346 Transformed cells were spread onto LB agar plates with 50 µg/mL ampicillin and incubated at 37°C
- 347 overnight. Selected colonies were cultured overnight. Plasmids were isolated using the QIAprep Spin
- 348 Miniprep Kit (Qiagen) and the successful introduction of the desired mutations was validated by DNA
- 349 sequencing with the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems).
- 350

351 Cell culture, transfection, RNA extraction, and reverse transcription

- Human embryonic kidney 293T (HEK293T) cells were cultured in the Dulbecco's modified Eagle's
- 353 medium (BioWhittaker) with 10% fetal calf serum (Eurobio). 3.5 × 10⁵ cells were seeded per well in 6-
- well plates 24 h before transfection. For conventional RT-PCR analyses, 1 µg wild-type or variant
- plasmid, mixed with 2 μL jetPEI DNA transfection reagent (Polyplus-transfection), was used for
- transfection per well. For real-time quantitative RT-PCR analyses, 500 ng wild-type or variant plasmid
- was mixed with 500 ng pGL3-GP2 minigene for transfection [44, 46, 50]. Forty-eight hours after
- transfection, total RNA was extracted using the RNeasy Mini Kit (Qiagen). RT was performed with 200
- U SuperScript III Reverse Transcriptase (Invitrogen), 500 μM dNTPs, 4 μL 5 × First-Strand Buffer, 5 mM
- dithiothreitol, 2.5 µM 20mer-oligo (dT), and 1 µg total RNA. The resulting complementary DNA (cDNA)
- were treated with 2U RNaseH (Invitrogen) to degrade the remaining RNA.
- 362

363 Conventional RT-PCR analyses and sequencing of the resulting products

- $364 \qquad \text{Conventional RT-PCR was performed in a 25-\mu L reaction mixture containing 12.5 } \mu L \ \text{HotStarTaq}$
- 365 Master Mix (Qiagen), 1 µL cDNA, and 0.4 µM each primer (5'-GGAGACCCAAGCTGGCTAGT-3'
- 366 (forward) and 5'-AGACCGAGGAGAGGGGTTAGG-3' (reverse) for TA cloning-obtained plasmids (both
- 367 primers are located within the pcDNA3.1/V5-His-TOPO vector sequence); 5'-
- 368 TAATACGACTCACTATAGGG-3' (forward) and 5'-TAGAAGGCACAGTCGAGG-3' (reverse) for in-
- fusion cloning-obtained plasmids (both primers are located within the pcDNA3.1(+) vector sequence)).
- The PCR program had an initial denaturation step at 95°C for 15 min, followed by 30 cycles of
- denaturation at 94°C for 45 s, annealing at 58°C for 45 s, and extension at 72°C for 1 min/kb (in the step
- to screen wild-type genes for which RT-PCR analysis of transfected cells generated a single or quasi-
- 373 single band of expected size) or for 2 min (in the step to analyze the splicing outcomes of 5'SS GT>GC
- mutations), and a final extension step at 72°C for 10 min. RT-PCR products of a single band were
- 375 cleaned by ExoSAP-IT (Affymetrix). In the case of multiple bands, the band corresponding to the
- 376 normal-sized product was excised from the agarose gel and then purified by QIAquick Gel Extraction Kit
- 377 (Qiagen). Sequencing primers were those used for the RT-PCR analyses. Sequencing reaction was
- performed by means of the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems).
- 379
- 380 Quantitation of the relative level of correctly spliced transcripts in artificially introduced GT>GC
- 381 mutations

4	1
-	÷.

382	The relative level of correctly spliced transcripts in association with GT>GC mutations that generated
383	only wild-type transcripts (confirmed by Sanger sequencing) was determined by real-time quantitative
384	RT-PCR analyses, essentially as described elsewhere [44, 46, 50]. Results were from three
385	independent transfection experiments, with each experiment being performed in three replicates.
386	
387	Pictogram Analysis of the 9-bp 5'SS Signal Sequences Associated with 5'SS GT>GC mutations
388	The 9-bp canonical 5'SS signal sequences of the currently studied disease-associated and artificially
389	introduced GT>GC mutations were extracted from the UCSC Genome Browser
390	(https://genome.ucsc.edu/). The respective pictograms were constructed using WebLogo
391	(http://weblogo.berkeley.edu/).
392	
393	In Silico Splicing Prediction
394	In silico splicing prediction was performed by means of Alamut® Visual v.2.11 rev. 0
395	(https://www.interactive-biosoftware.com/; Interactive Biosoftware, Rouen, France) under default
396	conditions.
397	
398	Acknowledgements
399	We are grateful to the original authors who reported the disease-causing 5'SS GT>GC mutations
400	studied here. We thank Nicolas Tomat and Léhna Bouchama (Brest, France) for technical assistance.
401	
402	Funding
403	J.H.L., a joint PhD student between the Changhai Hospital and INSERM U1078, was in receipt of a 20-
404	month scholarship from the China Scholarship Council (No. 201706580018). Support for this study
405	came from the Institut National de la Santé et de la Recherche Médicale (INSERM) and the
406	Etablissement Français du Sang (EFS), France; the National Natural Science Foundation of China
407	(81470884 (to Z.L.)), 81770636 (to Z.L.) and 81700565 (to W.B.Z.)), the Shuguang Program of
408	Shanghai (15SG33 (to Z.L.)), the Chang Jiang Scholars Program of Ministry of Education (Q2015190
409	(to Z.L.)), and the Scientific Innovation Program of Shanghai Municipal Education Committee (to Z.L.),
410	China. M.M., M.H. and D.N.C. acknowledge financial support from Qiagen Inc. through a License
411	Agreement with Cardiff University.
412	
413	REFERENCES
414	1. Turunen JJ, Niemela EH, Verma B, Frilander MJ. The significant other: splicing by the minor
415	spliceosome. Wiley Interdiscip Rev RNA. 2013;4:61-76.
416	2. Parada GE, Munita R, Cerda CA, Gysling K. A comprehensive survey of non-canonical splice
417	sites in the human transcriptome. Nucleic Acids Res. 2014;42:10564-78.
418 419	3. Verma B, Akinyi MV, Norppa AJ, Frilander MJ. Minor spliceosome and disease. Semin Cell Dev Biol. 2018;79:103-12.
420	 Sharp PA, Burge CB. Classification of introns: U2-type or U12-type. Cell. 1997;91:875-9.
421	5. Papasaikas P, Valcarcel J. The spliceosome: the ultimate RNA chaperone and sculptor. Trends
422	Biochem Sci. 2016;41:33-45.

423 6. Mount SM. A catalogue of splice junction sequences. Nucleic Acids Res. 1982;10:459-72.

424	7.	Burset M, Seledtsov IA, Solovyev VV. Analysis of canonical and non-canonical splice sites in
425		mammalian genomes. Nucleic Acids Res. 2000;28:4364-75.
426	8.	Abril JF, Castelo R, Guigo R. Comparison of splice sites in mammals and chicken. Genome Res.
427		2005;15:111-9.
428	9.	Roca X, Akerman M, Gaus H, Berdeja A, Bennett CF, Krainer AR. Widespread recognition of 5'
429		splice sites by noncanonical base-pairing to U1 snRNA involving bulged nucleotides. Genes
430		Dev. 2012;26:1098-109.
431	10.	Roca X, Krainer AR, Eperon IC. Pick one, but be quick: 5' splice sites and the problems of too
432		many choices. Genes Dev. 2013;27:129-44.
433	11.	Wong MS, Kinney JB, Krainer AR. Quantitative activity profile and context dependence of all
434		human 5' splice sites. Mol Cell. 2018;71:1012-26 e3.
435	12.	Mount SM, Pettersson I, Hinterberger M, Karmas A, Steitz JA. The U1 small nuclear RNA-
436		protein complex selectively binds a 5' splice site in vitro. Cell. 1983;33:509-18.
437	13.	Kramer A, Keller W, Appel B, Luhrmann R. The 5' terminus of the RNA moiety of U1 small
438		nuclear ribonucleoprotein particles is required for the splicing of messenger RNA precursors.
439		Cell. 1984;38:299-307.
440	14.	Zhuang Y, Weiner AM. A compensatory base change in U1 snRNA suppresses a 5' splice site
441		mutation. Cell. 1986;46:827-35.
442	15.	Kondo Y, Oubridge C, van Roon AM, Nagai K. Crystal structure of human U1 snRNP, a small
443	15.	nuclear ribonucleoprotein particle, reveals the mechanism of 5' splice site recognition. Elife.
444		2015;4.
445	16.	Dodgson JB, Engel JD. The nucleotide sequence of the adult chicken alpha-globin genes. J Biol
446	10.	Chem. 1983;258:4623-9.
440	17.	Erbil C, Niessing J. The primary structure of the duck alpha D-globin gene: an unusual 5' splice
448	17.	junction sequence. EMBO J. 1983;2:1339-43.
	10	King CR, Piatigorsky J. Alternative RNA splicing of the murine alpha A-crystallin gene: protein-
449	18.	
450	10	coding information within an intron. Cell. 1983;32:707-12.
451	19.	Burset M, Seledtsov IA, Solovyev VV. SpliceDB: database of canonical and non-canonical
452	20	mammalian splice sites. Nucleic Acids Res. 2001;29:255-9.
453	20.	Sheth N, Roca X, Hastings ML, Roeder T, Krainer AR, Sachidanandam R. Comprehensive splice-
454	24	site analysis using comparative genomics. Nucleic Acids Res. 2006;34:3955-67.
455	21.	Churbanov A, Winters-Hilt S, Koonin EV, Rogozin IB. Accumulation of GC donor splice signals in
456		mammals. Biol Direct. 2008;3:30.
457	22.	Erkelenz S, Theiss S, Kaisers W, Ptok J, Walotka L, Muller L, et al. Ranking noncanonical 5' splice
458		site usage by genome-wide RNA-seq analysis and splicing reporter assays. Genome Res. 2018
459		Oct 24. doi: 10.1101/gr.235861.118. [Epub ahead of print].
460	23.	Aebi M, Hornig H, Padgett RA, Reiser J, Weissmann C. Sequence requirements for splicing of
461		higher eukaryotic nuclear pre-mRNA. Cell. 1986;47:555-65.
462	24.	Aebi M, Hornig H, Weissmann C. 5' cleavage site in eukaryotic pre-mRNA splicing is
463		determined by the overall 5' splice region, not by the conserved 5' GU. Cell. 1987;50:237-46.
464	25.	Pagani F, Buratti E, Stuani C, Bendix R, Dork T, Baralle FE. A new type of mutation causes a
465		splicing defect in ATM. Nat Genet. 2002;30:426-9.
466	26.	Kralovicova J, Hwang G, Asplund AC, Churbanov A, Smith CI, Vorechovsky I. Compensatory
467		signals associated with the activation of human GC 5' splice sites. Nucleic Acids Res.
468		2011;39:7077-91.
469	27.	Zhang XH, Arias MA, Ke S, Chasin LA. Splicing of designer exons reveals unexpected complexity
470		in pre-mRNA splicing. RNA. 2009;15:367-76.
471	28.	De Conti L, Baralle M, Buratti E. Exon and intron definition in pre-mRNA splicing. Wiley
472		Interdiscip Rev RNA. 2013;4:49-60.
473	29.	Boehm V, Britto-Borges T, Steckelberg AL, Singh KK, Gerbracht JV, Gueney E, et al. Exon
474		junction complexes suppress spurious splice sites to safeguard rranscriptome integrity. Mol

475 Cell. 2018;72:482-95 e7.

476	30.	Ramalho AS, Beck S, Meyer M, Penque D, Cutting GR, Amaral MD. Five percent of normal
477		cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of
478		pulmonary disease in cystic fibrosis. Am J Respir Cell Mol Biol. 2002;27:619-27.
479	31.	Raraigh KS, Han ST, Davis E, Evans TA, Pellicore MJ, McCague AF, et al. Functional assays are
480		essential for interpretation of missense variants associated with variable expressivity. Am J
481		Hum Genet. 2018;102:1062-77.
482	32.	Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The Human Gene Mutation
483		Database: towards a comprehensive repository of inherited mutation data for medical
484		research, genetic diagnosis and next-generation sequencing studies. Hum Genet.
485		2017;136:665-77.
486	33.	Desviat LR, Clavero S, Perez-Cerda C, Navarrete R, Ugarte M, Perez B. New splicing mutations
487		in propionic acidemia. J Hum Genet. 2006;51:992-7.
488	34.	Soudais C, de Villartay JP, Le Deist F, Fischer A, Lisowska-Grospierre B. Independent mutations
489		of the human CD3-epsilon gene resulting in a T cell receptor/CD3 complex immunodeficiency.
490		Nat Genet. 1993;3:77-81.
491	35.	Lin P, Li W, Wen B, Zhao Y, Fenster DS, Wang Y, et al. Novel PNPLA2 gene mutations in Chinese
492		Han patients causing neutral lipid storage disease with myopathy. J Hum Genet. 2012;57:679-
493		81.
494	36.	Seyama K, Nonoyama S, Gangsaas I, Hollenbaugh D, Pabst HF, Aruffo A, et al. Mutations of the
495	50.	CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM
496		syndrome. Blood. 1998;92:2421-34.
497	37.	Bartolo C, Papp AC, Snyder PJ, Sedra MS, Burghes AH, Hall CD, et al. A novel splice site
498	57.	mutation in a Becker muscular dystrophy patient. J Med Genet. 1996;33:324-7.
498	38.	Hastbacka J, Kerrebrock A, Mokkala K, Clines G, Lovett M, Kaitila I, et al. Identification of the
	50.	
500	20	Finnish founder mutation for diastrophic dysplasia (DTD). Eur J Hum Genet. 1999;7:664-70.
501	39.	Muller JS, Piko H, Schoser BG, Schlotter-Weigel B, Reilich P, Gurster S, et al. Novel splice site
502		mutation in the caveolin-3 gene leading to autosomal recessive limb girdle muscular
503	10	dystrophy. Neuromuscul Disord. 2006;16:432-6.
504	40.	Aoyagi Y, Kobayashi H, Tanaka K, Ozawa T, Nitta H, Tsuji S. A de novo splice donor site
505		mutation causes in-frame deletion of 14 amino acids in the proteolipid protein in Pelizaeus-
506		Merzbacher disease. Ann Neurol. 1999;46:112-5.
507	41.	Kume K, Masamune A, Kikuta K, Shimosegawa T. [-215G>A; IVS3+2T>C] mutation in the SPINK1
508		gene causes exon 3 skipping and loss of the trypsin binding site. Gut. 2006;55:1214.
509	42.	Zou WB, Boulling A, Masson E, Cooper DN, Liao Z, Li ZS, et al. Clarifying the clinical relevance of
510		SPINK1 intronic variants in chronic pancreatitis. Gut. 2016;65:884-6.
511	43.	Zou WB, Masson E, Boulling A, Cooper DN, Li ZS, Liao Z, et al. Digging deeper into the intronic
512		sequences of the SPINK1 gene. Gut. 2016;65:1055-6.
513	44.	Boulling A, Chen JMC, I., Férec C. Is the SPINK1 p.Asn34Ser missense mutation per se the true
514		culprit within its associated haplotype? WebmedCentral GENETICS. 2012;3:WMC003084
515		(Available at: https://www.webmedcentral.com/article_view/3084). Accessed 14 November
516		2018.
517	45.	Fu XD, Ares M, Jr. Context-dependent control of alternative splicing by RNA-binding proteins.
518		Nat Rev Genet. 2014;15:689-701.
519	46.	Zou WB, Boulling A, Masamune A, Issarapu P, Masson E, Wu H, et al. No association between
520		CEL-HYB hybrid allele and chronic pancreatitis in Asian populations. Gastroenterology.
521		2016;150:1558-60 e5.
522	47.	Lykke-Andersen S, Jensen TH. Nonsense-mediated mRNA decay: an intricate machinery that
523		shapes transcriptomes. Nat Rev Mol Cell Biol. 2015;16:665-77.
524	48.	Popp MW, Maquat LE. Leveraging rules of nonsense-mediated mRNA decay for genome
525		engineering and personalized medicine. Cell. 2016;165:1319-22.

526 527	49.	Pereverzev AP, Gurskaya NG, Ermakova GV, Kudryavtseva EI, Markina NM, Kotlobay AA, et al. Method for quantitative analysis of nonsense-mediated mRNA decay at the single cell level. Sci
528		Rep. 2015;5:7729.
529	50.	Zou WB, Wu H, Boulling A, Cooper DN, Li ZS, Liao Z, et al. <i>In silico</i> prioritization and further
530		functional characterization of SPINK1 intronic variants. Hum Genomics. 2017;11:7.
531	51.	Wu H, Boulling A, Cooper DN, Li ZS, Liao Z, Chen JM, et al. <i>In vitro</i> and <i>in silico</i> evidence against
532		a significant effect of the SPINK1 c.194G>A variant on pre-mRNA splicing. Gut. 2017;66:2195-6.
533	52.	Ota Y, Masamune A, Inui K, Kume K, Shimosegawa T, Kikuyama M. Phenotypic variability of the
534 535		homozygous IVS3+2T>C mutation in the serine protease inhibitor Kazal type 1 (<i>SPINK1</i>) gene in patients with chronic pancreatitis. Tohoku J Exp Med. 2010;221:197-201.
536	53.	Venet T, Masson E, Talbotec C, Billiemaz K, Touraine R, Gay C, et al. Severe infantile isolated
537		exocrine pancreatic insufficiency caused by the complete functional loss of the SPINK1 gene.
538		Hum Mutat. 2017;38:1660-5.
539	54.	Yilmaz D, Cogulu O, Ozkinay F, Kavakli K, Roos D. A novel mutation in the DIA1 gene in a
540		patient with methemoglobinemia type II. Am J Med Genet A. 2005;133A:101-2.
541	55.	Frischknecht H, Dutly F, Walker L, Nakamura-Garrett LM, Eng B, Waye JS. Three new beta-
542		thalassemia mutations with varying degrees of severity. Hemoglobin. 2009;33:220-5.
543	56.	Hladnik U, Nyhan WL, Bertelli M. Variable expression of HPRT deficiency in 5 members of a
544		family with the same mutation. Arch Neurol. 2008;65:1240-3.
545	57.	Wuhl E, Kogan J, Zurowska A, Matejas V, Vandevoorde RG, Aigner T, et al.
546		Neurodevelopmental deficits in Pierson (microcoria-congenital nephrosis) syndrome. Am J
547		Med Genet A. 2007;143:311-9.
548	58.	Bar DZ, Arlt MF, Brazier JF, Norris WE, Campbell SE, Chines P, et al. A novel somatic mutation
549		achieves partial rescue in a child with Hutchinson-Gilford progeria syndrome. J Med Genet.
550		2017;54:212-6.
551	59.	Al-Mahdili HA, Hooper AJ, Sullivan DR, Stewart PM, Burnett JR. A mild case of
552		abetalipoproteinaemia in association with subclinical hypothyroidism. Ann Clin Biochem.
553		2006;43:516-9.
554	60.	Kajihara S, Hisatomi A, Mizuta T, Hara T, Ozaki I, Wada I, et al. A splice mutation in the human
555		canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome.
556		Biochem Biophys Res Commun. 1998;253:454-7.
557	61.	Fukao T, Yamaguchi S, Scriver CR, Dunbar G, Wakazono A, Kano M, et al. Molecular studies of
558		mitochondrial acetoacetyl-coenzyme A thiolase deficiency in the two original families. Hum
559		Mutat. 1993;2:214-20.
560	62.	Lagier-Tourenne C, Tazir M, Lopez LC, Quinzii CM, Assoum M, Drouot N, et al. ADCK3, an
561		ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10
562		deficiency. Am J Hum Genet. 2008;82:661-72.
563	63.	Dolcini L, Caridi G, Dagnino M, Sala A, Gokce S, Sokucu S, et al. Analbuminemia produced by a
564		novel splicing mutation. Clin Chem. 2007;53:1549-52.
565	64.	Infante JB, Alvelos MI, Bastos M, Carrilho F, Lemos MC. Complete androgen insensitivity
566		syndrome caused by a novel splice donor site mutation and activation of a cryptic splice donor
567		site in the androgen receptor gene. J Steroid Biochem Mol Biol. 2016;155:63-6.
568	65.	Rios M, Storry JR, Hue-Roye K, Chung A, Reid ME. Two new molecular bases for the Dombrock
569		null phenotype. Br J Haematol. 2002;117:765-7.
570	66.	Das S, Levinson B, Whitney S, Vulpe C, Packman S, Gitschier J. Diverse mutations in patients
571		with Menkes disease often lead to exon skipping. Am J Hum Genet. 1994;55:883-9.
572	67.	Hopp K, Heyer CM, Hommerding CJ, Henke SA, Sundsbak JL, Patel S, et al. B9D1 is revealed as a
573		novel Meckel syndrome (MKS) gene by targeted exon-enriched next-generation sequencing
574		and deletion analysis. Hum Mol Genet. 2011;20:2524-34.
575	68.	Haire RN, Ohta Y, Strong SJ, Litman RT, Liu Y, Prchal JT, et al. Unusual patterns of exon skipping
576		in Bruton tyrosine kinase are associated with mutations involving the intron 17 3' splice site.

Am J Hum Genet. 1997;60:798-807.

578 579	69.	Rahner N, Nuernberg G, Finis D, Nuernberg P, Royer-Pokora B. A novel <i>C8orf37</i> splice mutation and genotype-phenotype correlation for cone-rod dystrophy. Ophthalmic Genet. 2016;37:294-
580		300.
581	70.	Tosetto E, Ghiggeri GM, Emma F, Barbano G, Carrea A, Vezzoli G, et al. Phenotypic and genetic
582		heterogeneity in Dent's diseasethe results of an Italian collaborative study. Nephrol Dial
583		Transplant. 2006;21:2452-63.
584	71.	Nicholls AC, Valler D, Wallis S, Pope FM. Homozygosity for a splice site mutation of the COL1A2
585		gene yields a non-functional pro(alpha)2(I) chain and an EDS/OI clinical phenotype. J Med
586		Genet. 2001;38:132-6.
587	72.	Haas JT, Winter HS, Lim E, Kirby A, Blumenstiel B, DeFelice M, et al. DGAT1 mutation is linked
588		to a congenital diarrheal disorder. J Clin Invest. 2012;122:4680-4.
589	73.	Wibawa T, Takeshima Y, Mitsuyoshi I, Wada H, Surono A, Nakamura H, et al. Complete
590		skipping of exon 66 due to novel mutations of the dystrophin gene was identified in two
591		Japanese families of Duchenne muscular dystrophy with severe mental retardation. Brain Dev.
592		2000;22:107-12.
593	74.	Ahmed I, Mittal K, Sheikh TI, Vasli N, Rafiq MA, Mikhailov A, et al. Identification of a
594		homozygous splice site mutation in the dynein axonemal light chain 4 gene on 22q13.1 in a
595		large consanguineous family from Pakistan with congenital mirror movement disorder. Hum
596		Genet. 2014;133:1419-29.
597	75.	Hermans MM, van Leenen D, Kroos MA, Reuser AJ. Mutation detection in glycogen storage-
598		disease type II by RT-PCR and automated sequencing. Biochem Biophys Res Commun.
599		1997;241:414-8.
600	76.	Sobrier ML, Maghnie M, Vie-Luton MP, Secco A, di Iorgi N, Lorini R, et al. Novel HESX1
601		mutations associated with a life-threatening neonatal phenotype, pituitary aplasia, but
602		normally located posterior pituitary and no optic nerve abnormalities. J Clin Endocrinol Metab.
603		2006;91:4528-36.
604	77.	Moran CJ, Walters TD, Guo CH, Kugathasan S, Klein C, Turner D, et al. IL-10R polymorphisms
605		are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis. 2013;19:115-23.
606	78.	Humbert C, Silbermann F, Morar B, Parisot M, Zarhrate M, Masson C, et al. Integrin alpha 8
607		recessive mutations are responsible for bilateral renal agenesis in humans. Am J Hum Genet.
608		2014;94:288-94.
609	79.	Vockley J, Rogan PK, Anderson BD, Willard J, Seelan RS, Smith DI, et al. Exon skipping in <i>IVD</i>
610		RNA processing in isovaleric acidemia caused by point mutations in the coding region of the
611		IVD gene. Am J Hum Genet. 2000;66:356-67.
612	80.	Villa A, Sironi M, Macchi P, Matteucci C, Notarangelo LD, Vezzoni P, et al. Monocyte function in
613		a severe combined immunodeficient patient with a donor splice site mutation in the Jak3
614		gene. Blood. 1996;88:817-23.
615	81.	Allamand V, Sunada Y, Salih MA, Straub V, Ozo CO, Al-Turaiki MH, et al. Mild congenital
616		muscular dystrophy in two patients with an internally deleted laminin alpha2-chain. Hum Mol
617		Genet. 1997;6:747-52.
618	82.	Nichols WC, Seligsohn U, Zivelin A, Terry VH, Hertel CE, Wheatley MA, et al. Mutations in the
619		ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of
620		coagulation factors V and VIII. Cell. 1998;93:61-70.
621	83.	Wood-Trageser MA, Gurbuz F, Yatsenko SA, Jeffries EP, Kotan LD, Surti U, et al. MCM9
622		mutations are associated with ovarian failure, short stature, and chromosomal instability. Am J
623		Hum Genet. 2014;95:754-62.
624	84.	Gok F, Crettol LM, Alanay Y, Hacihamdioglu B, Kocaoglu M, Bonafe L, et al. Clinical and
625		radiographic findings in two brothers affected with a novel mutation in matrix
626		metalloproteinase 2 gene. Eur J Pediatr. 2010;169:363-7.
627	85.	Martin CA, Murray JE, Carroll P, Leitch A, Mackenzie KJ, Halachev M, et al. Mutations in genes
628		encoding condensin complex proteins cause microcephaly through decatenation failure at
629		mitosis. Genes Dev. 2016;30:2158-72.

630 631 632	86.	Tanugi-Cholley LC, Issartel JP, Lunardi J, Freycon F, Morel F, Vignais PV. A mutation located at the 5' splice junction sequence of intron 3 in the p67phox gene causes the lack of p67phox mRNA in a patient with chronic granulomatous disease. Blood. 1995;85:242-9.
633 634 635	87.	Zanni G, Saillour Y, Nagara M, Billuart P, Castelnau L, Moraine C, et al. Oligophrenin 1 mutations frequently cause X-linked mental retardation with cerebellar hypoplasia. Neurology. 2005;65:1364-9.
636 637 638	88.	Matsuura T, Hoshide R, Komaki S, Kiwaki K, Endo F, Nakamura S, et al. Identification of two new aberrant splicings in the ornithine carbamoyltransferase (<i>OCT</i>) gene in two patients with early and late onset OCT deficiency. J Inherit Metab Dis. 1995;18:273-82.
639 640 641	89.	Shimozawa N, Nagase T, Takemoto Y, Suzuki Y, Fujiki Y, Wanders RJ, et al. A novel aberrant splicing mutation of the <i>PEX16</i> gene in two patients with Zellweger syndrome. Biochem Biophys Res Commun. 2002;292:109-12.
642 643	90.	Biancheri R, Grossi S, Regis S, Rossi A, Corsolini F, Rossi DP, et al. Further genotype-phenotype correlation emerging from two families with <i>PLP1</i> exon 4 skipping. Clin Genet. 2014;85:267-72.
644 645	91.	Aldahmesh MA, Mohamed JY, Alkuraya FS. A novel mutation in <i>PRDM5</i> in brittle cornea syndrome. Clin Genet. 2012;81:198-9.
646 647	92.	Smith SB, Qu HQ, Taleb N, Kishimoto NY, Scheel DW, Lu Y, et al. Rfx6 directs islet formation and insulin production in mice and humans. Nature. 2010;463:775-80.
648 649	93.	Adly N, Alhashem A, Ammari A, Alkuraya FS. Ciliary genes <i>TBC1D32/C6orf170</i> and <i>SCLT1</i> are mutated in patients with OFD type IX. Hum Mutat. 2014;35:36-40.
650 651 652	94.	Sumegi J, Huang D, Lanyi A, Davis JD, Seemayer TA, Maeda A, et al. Correlation of mutations of the <i>SH2D1A</i> gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood. 2000;96:3118-25.
653 654 655	95.	Leman R, Gaildrat P, Gac GL, Ka C, Fichou Y, Audrezet MP, et al. Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort. Nucleic Acids Res. 2018;46:7913-23.

		case-oausing		ions and then	i i culcicu c				
Disease	Gene	Mutation	Reference	Zygosity	Generation of Wild-Type Transcripts ^a	SpliceSiteFinder-like (0-100) ^b	MaxEntScan (0-12) ^b	NNSPLICE (0-1) ^b	GeneSplicer (0-15) ^b
Dubin-Johnson syndrome	ABCC2	c.1967+2T>C	Kajihara et al. [60]	Homozygote	No	74.2→NS	7.4→NS	0.6→NS	1.8→NS
Acetoacetyl-CoA- thiolase deficiency	ACAT1	c.1163+2T>C	Fukao et al. [61]	Homozygote	No	76.8→74.1	6.9→NS	1.0→NS	NS
Ubiquinone deficiency with cerebellar ataxia	COQ8A	c.1398+2T>C	Lagier-Tourenne et al. [62]	Homozygote	No	76.9→75.2	6.4→NS	0.8→NS	4.6→NS
Analbuminaemia	ALB	c.1428+2T>C	Dolcini et al. [63]	Homozygote	No	78.9→70.8	5.6→NS	1.0→NS	NS
Androgen insensitivity syndrome	AR	c.2173+2T>C	Infante et al. [64]	Hemizygote	No	86.5→81.1	9.7→NS	1.0→NS	4.4→NS
Dombrock null allele	ART4	c.144+2T>C	Rios et al. [65]	Homozygote	No	81.8→79.9	7.8→NS	0.9→NS	4.1→NS
Menkes syndrome	ATP7A	c.1946+2T>C	Das et al. [66]	Hemizygote	No	78.6→75.5	9.5→NS	1.0→NS	3.8→NS
Meckel syndrome	B9D1	c.341+2T>C	Hopp et al. [67]	Hemizygote	No	81.0→78.7	9.4→NS	1.0→NS	8.2→NS
Agammaglobulinaemia	BTK	c.588+2T>C	Haire et al. [68]	Hemizygote	No	71.9→NS	7.5→NS	0.8→NS	4.0→NS
Cone-rod dystrophy	C8orf37	c.155+2T>C	Rahner et al. [69]	Homozygote	No	72.2→NS	1.6→NS	0.6→NS	2.1→NS
Autosomal recessive limb girdle muscular dystrophy	CAV3	c.114+2T>C	Muller et al. [39]	Homozygote	Yes	83.8→81.8	10.1→NS	1.0→NS	10.1→NS
Immunodeficiency	CD3E	c.520+2T>C	Soudais et al. [34]	Compound heterozygote	Yes (1-5%)	83.0→78.1	8.1→NS	1.0→NS	2.9→NS
Hyper-IgM syndrome	CD40LG	c.346+2T>C	Seyama et al [36]	Hemizygote	Yes (15%)	89.6→90.0	10.3→NS	1.0→NS	1.6→NS
Dent disease	CLCN5	c.205+2T>C	Tosetto et al. [70]	Hemizygote	No	84.8→82.1	10.0→NS	1.0→NS	NS
Ehlers-Danlos syndrome/Osteogenesis imperfecta	COL1A2	c.3105+2T>C	Nicholls et al. [71]	Homozygote	No	75.4→72.8	8.6→NS	0.9→NS	1.1→NS
Congenital diarrhoeal disorder	DGAT1	c.751+2T>C	Haas et al. [72]	Homozygote	No	78.6→NS	7.9→NS	1.0→NS	11.9→NS
Becker muscular dystrophy	DMD	c.8027+2T>C	Bartolo et al. [37]	Hemizygote	Yes (10%)	84.2→81.5	9.1→NS	1.0→NS	1.7→NS
Duchenne muscular dystrophy	DMD	c.9649+2T>C	Wibawa et al. [73]	Hemizygote	No	84.3→84.4	9.1→NS	1.0→NS	NS
Mirror movements (congenital)	DNAL4	c.153+2T>C	Ahmed et al. [74]	Homozygote	No	NS	7.4→NS	0.8→NS	9.7→NS
Glycogen storage disease 2	GAA	c.2331+2T>C	Hermans et al. [75]	Homozygote	No	86.4→76.7	11.5→NS	1.0→NS	13.6→NS
Pituitary aplasia	HESX1	c.357+2T>C	Sobrier et al. [76]	Homozygote	No	80.2→70.6	6.7→NS	0.8→NS	NS
Ulcerative colitis	IL10RA	c.688+2T>C	Moran et al. [77]	Homozygote	No	73.8→NS	7.0→NS	0.8→NS	2.7→NS
Renal hypodysplasia	ITGA8	c.2982+2T>C	Humbert et al. [78]	Homozygote	No	71.9→NS	5.8→NS	0.9→NS	NS
Isovaleric acidaemia	IVD	c.465+2T>C	Vockley et al. [79]	Homozygote	No	90.3→80.5	9.2→NS	1.0→NS	4.5→NS
Immunodeficiency (severe combined)	JAK3	c.2350+2T>C	Villa et al. [80]	Homozygote	No	NS	5.8→NS	NS	6.8→NS

657 Table 1. The 45 Informative Disease-Causing 5'SS GT>GC Mutations and their Predicted Splicing Effects*

Muscular dystrophy (merosin deficient)	LAMA2	c.3924+2T>C	Allamand et al. [81]	Homozygote	No	79.8→77.0	8.3→NS	0.8→NS	3.4→NS
Factor V and factor VIII deficiency (combined)	LMAN1	c.1149+2T>C	Nichols et al. [82]	Homozygote	No	79.8→70.6	8.1→NS	NS	NS
Primary amenorrhea & short stature	МСМ9	c.1732+2T>C	Wood-Trageser et al. [83]	Homozygote	No	NS	1.7→NS	NS	NS
Torg-Winchester syndrome	MMP2	c.658+2T>C	Gok et al. [84]	Homozygote	No	90.0→80.1	8.7→NS	1.0→NS	10.9→NS
Microcephaly	NCAPD2	c.4120+2T>C	Martin et al. [85]	Homozygote	No	84.2→81.5	9.1→NS	0.9→NS	7.1→NS
Chronic granulomatous disease	NCF2	c.257+2T>C	Tanugi-Cholley et al. [86]	Homozygote	No	84.8→84.7	9.8→NS	1.0→NS	5.3→NS
Mental retardation syndrome (X-linked)	OPHN1	c.154+2T>C	Zanni et al. [87]	Hemizygote	No	84.8→84.7	9.8→NS	1.0→NS	7.9→NS
Ornithine carbamoyltransferase deficiency	OTC	c.540+2T>C	Matsuura et al. [88]	Hemizygote	No	80.0→78.2	8.1→NS	0.6→NS	NS
Propionic acidaemia	PCCB	c.183+2T>C	Desviat et al. [33]	Homozygote	No	74.5→NS	8.5→NS	0.9→NS	9.7→NS
Propionic acidaemia	PCCB	c.1498+2T>C	Desviat et al.[33]	Homozygote	No	81.8→79.9	7.8→NS	0.7→NS	5.0→NS
Zellweger syndrome	PEX16	c.952+2T>C	Shimozawa et al. [89]	Homozygote	No	82.1→79.0	7.5→NS	1.0→NS	5.2→NS
Spastic tetraparesis/paraparesis	PLP1	c.622+2T>C	Biancheri et al. [90]	Hemizygote	No	86.8→77.2	10.1→NS	1.0→NS	6.2→NS
Pelizaeus-Merzbacher disease	PLP1	c.696+2T>C	Aoyagi et al. [40]	Hemizygote	Yes	92.6→85.9	10.0→NS	1.0→NS	6.5→NS
Neutral lipid storage disease with myopathy	PNPLA2	c.757+2T>C	Lin et al. [35]	Compound heterozygote	No	NS	8.7→NS	NS	8.3→NS
Brittle cornea syndrome	PRDM5	c.93+2T>C	Aldahmesh et al. [91]	Homozygote	No	85.3→78.5	8.2→NS	0.9→NS	10.6→NS
Diabetes (neonatal, with intestinal atresia)	RFX6	c.380+2T>C	Smith et al. [92]	Homozygote	No	78.7→NS	5.5→NS	0.6→NS	2.9→NS
Oro-facio-digital syndrome type IX	SCLT1	c.290+2T>C	Adly et al. [93]	Homozygote	No	87.5→87.1	8.9→NS	1.0→NS	NS
Lymphoproliferative syndrome (X-linked)	SH2D1A	c.137+2T>C	Sumegi et al. [94]	Hemizygote	No	71.1→NS	7.4→NS	0.4→NS	5.9→NS
Diastrophic dysplasia	SLC26A2	c26+2T>C	Hastbacks et al. [38]	Homozygote	Yes (5%)	87.3→77.7	7.7→NS	1.0→NS	11.5→NS
Chronic pancreatitis	SPINK1	c.194+2T>C	Kume et al. [41]	Homozygote	Yes	82.6→72.3	11.1→NS	1.0→NS	4.0→NS

*See Supplementary Table S1 for more information. ^aRelative expression level is indicated in parentheses wherever applicable. ^bPrediction was done under default conditions. NS, no score.


662 Table 2. Nature of the Sequenced 12 Aberrantly Spliced Transcripts*

Gene	Reference mRNA accession number	Mutation	Aberrant Transcripts
DBI	NM_001079862.2	IVS1+2T>C	 Activation of a cryptic 5'SS GT which is located 152 bp downstream of the normal one, resulting in the retention of the first 154 bp of the intron 1 sequence. Activation of a cryptic 5'SS GT which is located 28 bp downstream of the normal one, resulting in the retention of the first 30 bp of the intron 1 sequence.
		IVS3+2T>C	Exon 3 skipping
FABP7	NM_001446.4	IVS1+2T>C	Activation of a cryptic 5'SS GT which is located 2 bp downstream of the normal one, resulting in the retention of the first 4 bp of the intron 1 sequence.
		IVS2+2T>C	Activation of a cryptic 5'SS GT which is located 3 bp upstream of the normal one, resulting in the deletion of the last 5 bp of exon 1.
HESX1	NM_003865.2	IVS2+2T>C	Exon 2 skipping
		IVS3+2T>C	Exon 3 skipping
IL10	NM_000572.3	IVS1+2T>C	Activation of a cryptic 5'SS GT which is located 2 bp downstream of the normal one, resulting in the retention of the first 4 bp of the intron 1 sequence.
		IVS4+2T>C	Activation of a cryptic 5'SS GT which is located 19 bp upstream of the normal one, resulting in the deletion of the last 21 bp of exon 4.
PRSS2	NM_002770.3	IVS4+2T>C	Activation of a cryptic 5'SS GC which is located 15 bp upstream of the normal one, resulting in the deletion of the last 17 bp of exon 4.
SPINK1	NM_003122.3	IVS1+2T>C	Activation of a cryptic 5'SS GT which is located 138 bp downstream of the normal one, resulting in the retention of the first 140 bp of the intron 1 sequence.
UQCRB	NM_006294.4	IVS1+2T>C	Activation of a cryptic 5'SS GT which is located 10 bp upstream of the normal one, resulting in the deletion of the last 12 bp of exon 1.

663


*See Supplementary Figure S1 for the corresponding RT-PCR products





665 Figure 1. Background Information, Aims and Analytical Strategy of the Study

- 666 (A) Current knowledge of the canonical 5' splice sites (5'SS) GT and non-canonical 5'SS GC in the
- human genome in terms of their relative abundance of U2-type introns, their corresponding 9-bp 5'SS 667
- signal sequence position weight matrices (PWM) and their associated splicing outcomes. The two 668
- 669 PWM illustrative figures were taken from Leman et al. Novel diagnostic tool for prediction of variant
- 670 spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international
- 671 collaborative effort. Nucleic Acids Res. 2018;46(15):7913-7923 [95] (an Open Access article
- 672 distributed under the terms of the Creative Commons Attribution Non-Commercial License).
- (B) Illustration of the first experimental evidence showing that a 5'SS GT>GC mutation may retain the 673
- ability to generate wild-type transcripts, albeit at a much reduced level (~10% of normal in [23, 24]). 674
- 675 (C) Aim and analytical strategy of the study.



677

678 Figure 2. Qualitative Analysis of 5'SS GT>GC Mutations

(A) Illustration of the cell culture-based full-length gene splicing assay in the context of a 5'SS GT>GC
 mutation generating some wild-type transcripts. The two horizontal arrows indicate the primers (both
 located within the vector sequence) used to amplify normally spliced transcripts (and also aberrantly


682 spliced transcripts). F.L., full-length.

(B) RT-PCR analyses of HEK293T cells transfected with full-length *DBI*, *FATE1* and *PRSS2* gene

684 expression constructs carrying respectively the wild-type and 5'SS GT>GC mutations as examples.

Normal transcripts (confirmed by sequencing) resulting from two of the mutations are indicated by

arrows. IVS, InterVening Sequence (i.e., an intron). See Supplementary Figure S1 for all 103
 functionally analyzed 5'SS GT>GC mutations.




691

Figure 3. Quantitative Analysis Pertaining to the Relative Level of 5'SS GT>GC Mutation-

693 Derived Wild-Type Transcripts

(A) Illustration of one key feature of the quantitative RT-PCR analysis: co-transfection of a minigene 694 expression vector with respectively the full-length wild-type target gene expression vector and the full-695 length variant target gene expression vector. The minigene was constructed in pGL3 [44] whereas the 696 697 target gene was constructed in either pcDNA3.1/V5-His-TOPO vector or pcDNA3.1(+). The minigene was used as an internal control for quantifying the expression level of wild-type transcripts generated 698 699 from either the wild-type or variant target full-length gene. The horizontal arrows indicate the relative 700 positions of the primers used for this purpose. Note that for amplifying the target gene sequence, 701 either a primer pair comprising a forward vector-specific primer and a reverse gene-specific primer (as 702 illustrated) or alternatively a primer pair comprising a forward gene-specific primer and a reverse 703 vector-specific primer was used. This assay was performed exclusively for the 10 5'SS GT>GC 704 mutations that generated only wild-type transcripts. F.L., full-length. 705 (B) Quantitative RT-PCR-determined expression level of the mutant allele-derived correctly spliced transcripts relative to that derived from the corresponding wild-type allele (defined as 100%) in the 10 706 707 5'SS GT>GC mutations that generated only wild-type transcripts. Results were expressed as means ± 708 SD from three independent transfection experiments.




711

712 Figure 4. Pictogram Analysis of the 5'SSs Under Study

Comparison of the pictogram of the 122 5'SSs whose substitutions of GT by GC did not lead to the generation of normal transcripts (upper panel) and that of the 26 5'SSs whose substitutions of GT by GC generated normal transcripts (lower panel). Middle panel shows the 5' end sequence of U1 snRNA that is complementary to the 9-bp U2-type 5'SS signal sequence. 5'SS signal sequences are shown as RNA sequence.

- 718
- 719
- 720
- -
- 721
- 722
- 723



- 724
- 725

726 Figure 5. Functional Characterization of the HBB c.315+2T>C mutation

727 RT-PCR analyses of HEK293T cells transfected with full-length *HBB* gene expression constructs

- carrying respectively the wild-type and two 5'SS GT>GC mutations. Wild-type transcripts (confirmed
- by sequencing) resulting from the wild-type and the IVS2+2T>C (i.e., c.315+2T>C) mutation are
- indicated by arrows. The *HBB* c.315+2T>C mutation was previously reported to be associated with a
- mild phenotype [55]. IVS, InterVening Sequence (i.e., an intron).
- 732